Celltrion Inc. is gearing up to file a marketing authorization with the European Medicines Agency for Remsima SC, a subcutaneous (SC) version of its autoimmune disease therapeutic antibody infliximab, a biosimilar version of Johnson & Johnson's Remicade, following the completion of a Phase III clinical trial.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?